No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy

Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis?

(2015) Jaime Imitola et al.   JAMA Neurology

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

Subclinical MRI disease activity influences cognitive performance in MS patients

(2015) Alfredo Damasceno et al.   Multiple Sclerosis and Related Disorders

Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations

(2014) Mark S. Freedman et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Disease Activity Free Status

(2014) Carolyn J. Bevan et al.   JAMA Neurology

Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: Implications for monitoring atrophy in clinical studies

(2014) Kunio Nakamura et al.   NeuroImage-Clinical

Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model

(2014) Martin Stangel et al.   Therapeutic Advances in Neurological Disorders

Brain atrophy and lesion load predict long term disability in multiple sclerosis

(2013) Veronica Popescu et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Measurement and clinical effect of grey matter pathology in multiple sclerosis

(2012) Jeroen JG Geurts et al.   LANCET NEUROLOGY

Within-subject template estimation for unbiased longitudinal image analysis

(2012) Martin Reuter et al.   NEUROIMAGE

Disease activity free status in MS

(2011) Fred D. Lublin   Multiple Sclerosis and Related Disorders

Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline

(2010) Sarah A. Morrow et al.   CLINICAL NEUROPSYCHOLOGIST

Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?

(2010) LVAE Bosma et al.   Multiple Sclerosis Journal

Reliability, practice effects, and change indices for Rao’s brief repeatable battery

(2010) Emilio Portaccio et al.   Multiple Sclerosis Journal

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Gray matter atrophy is related to long-term disability in multiple sclerosis

(2008) Leonora K. Fisniku et al.   ANNALS OF NEUROLOGY

Multiple Sclerosis: An Immune or Neurodegenerative Disorder?

(2008) Bruce D. Trapp et al.   Annual Review of Neuroscience

The prediction of Change: Normative neuropsychological trajectories

(2008) Deborah K. Attix et al.   CLINICAL NEUROPSYCHOLOGIST